Sharma; Pradeep K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Sharma; Pradeep K..The latest application filed is for "pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine".

Company Profile

2.6.13

Sharma; Pradeep K. - Westford MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine App 20220249524 - Verwijs; Dauntel S. ; et al.	2022-08-11
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,384,086 - Murray , et al. July 12, 2	2022-07-12
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,279,705 - Murray , et al. March 22, 2	2022-03-22
Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine App 20210401860 - Verwijs; Dauntel S. ; et al.	2021-12-30
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,897 - Murray , et al. December 7, 2	2021-12-07
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,895 - Murray , et al. December 7, 2	2021-12-07
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,896 - Murray , et al. December 7, 2	2021-12-07
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210340149 - Murray; Christopher K. ; et al.	2021-11-04
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277011 - Murray; Christopher K. ; et al.	2021-09-09
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277012 - Murray; Christopher K. ; et al.	2021-09-09
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277010 - Murray; Christopher K. ; et al.	2021-09-09
Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine App 20210186994 - Verwijs; Dauntel S. ; et al.	2021-06-24
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210024527 - Murray; Christopher K. ; et al.	2021-01-28
Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 10,662,197 - Murray , et al.	2020-05-26
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl App 20190169196 - Murray; Christopher K. ; et al.	2019-06-06
Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpi- perazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine App 20180256610 - Verwijs; Dauntel S. ; et al.	2018-09-13
Preparation of (+)-Catechin, (-)-Epicatechin, (-)-Catechin, and (+)-Epicatechin and Their 5,7,3',4'-Tetra-O-Benzyl Analogues App 20100048920 - Romanczyk, JR.; Leo J. ; et al.	2010-02-25
Processes for the preparation of protected-(+)-catechin and (-)-epicatechin monomers, for coupling the protected monomers with an activated, protected epicatechin monomer, and for the preparation of epicatechin-(4B,8)-epicatechin or -catechin dimers and their digallates App 20070004796 - Romanczyk; Leo JR. ; et al.	2007-01-04
Stereoselective synthesis of 1,2-disubstituted cycloalkyls App 20040049049 - Jurayj, Jurjus F. ; et al.	2004-03-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.